The mutation is a T-to-A transversion at codon 162 in exon 5. This is predicted to alter a leucine to a glycine in the beta-strand B6. TPI1 activity in heterozygotes is 50% that of wild-type in blood; and also reduced in liver, lung, spleen, kidney, brain, heart and muscle. (J:25049)